[Form 4] USANA Health Sciences Inc Insider Trading Activity

Rhea-AI Filing Summary

Gilbert A. Fuller, a director of USANA Health Sciences Inc (USNA), reported a sale of 1,058 shares of common stock on 08/07/2025 at approximately $29.1014 per share. The Form 4 lists the transaction as a sale and shows 0 shares beneficially owned by Fuller following the reported transaction, with ownership held directly. The filing discloses the required Section 16 details for the transaction.

Positive

• None.

Negative

• Director sale reported: Gilbert A. Fuller sold 1,058 shares at $29.1014 per share and is shown with 0 shares beneficially owned after the transaction.

Insights

Financial Analyst

TL;DR: A reported director sale of 1,058 USNA shares at $29.1014, recorded on Form 4; impact appears routine.

The filing shows a director-identified sale of 1,058 shares on 08/07/2025 at $29.1014 per share, ending with 0 shares beneficially owned. This is a direct disposition disclosed under Section 16. As reported, the item is a documented insider sale with no other concurrent transactions or derivative activity disclosed.

Corporate Governance Expert

TL;DR: Insider sale fully disclosed on Form 4; governance process followed through a signed filing.

The Form 4 names Gilbert A. Fuller as the reporting person and marks his role as a director. The transaction is recorded as a sale with direct ownership indicated and the submission includes an authorized signature by an attorney-in-fact. The disclosure meets reporting requirements without additional context on motive or related arrangements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FULLER GILBERT A

(Last) (First) (Middle)

3838 WEST PARKWAY BLVD

(Street)

SALT LAKE CITY UT 84120

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
USANA HEALTH SCIENCES INC [ USNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2025		S		1,058	D	$29.1014	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Joshua Foukas, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the USNA Form 4 report?

The Form 4 reports a sale of 1,058 common shares of USANA Health Sciences (USNA).

When was the USNA insider transaction executed?

The reported transaction date is 08/07/2025.

At what price were the USNA shares sold?

The sale price is listed as $29.1014 per share.

How many USNA shares did the reporting person own after the sale?

The Form 4 shows 0 shares beneficially owned by Gilbert A. Fuller following the reported transaction.

What is the reporting person’s relationship to USANA?

Gilbert A. Fuller is identified on the form as a Director of USANA Health Sciences Inc.